Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Clinical trial NCT03989115 · COMPLETED
Trial details
- NCT number
- NCT03989115
- Sponsor
- Revolution Medicines, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-02
- Primary completion
- 2022-02-08
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.